| Why biotech is catching this rotation: First, it's a safe haven sector. When Microsoft and Palantir and AMD and Nvidia start selling off, that money flows into what's commonly considered defensive - and that lands right with the Pfizers and Mercks and Novos and Lillys. Second, there's an M&A boom happening that most people aren't paying attention to. All these big drug makers need pipelines. They've got patent cliffs coming up. Pfizer's got a huge one. That's why they bought Seagen. Lilly is picking up companies even though they don't need to. Merck might be in a deal for RVMD. There's three or four other candidates out there. We have one as a catalyst pick that we're only sharing with paid subscribers. But that sector is going to be on fire. We have trades in the war room on XBI. We sold it earlier this year. The biotech sector just hit a 52-week high - maybe an all-time high. Think about what happened pre-COVID. Pfizer was trading at $25 a share. They had the COVID vaccine come out, and Pfizer stock went from $26 to $62 in a year. They took the money from COVID to go buy Seagen. But they're facing patent cliffs over the next three years, and they've got stuff to replace it. Here's how Pfizer works: Pfizer's got a massive marketing machine. When they get a drug, they know how to market it. Viagra. Lipitor. They know how to reach a broad market. The drugs they have in their pipeline right now - once they come online a year or two from now, that's when you see the growth. This isn't just about Pfizer. It's about an entire sector that hasn't reverted to the mean, but their mean is a lot higher than where they're trading now. Your Action Plan XBI is the vehicle. We've already traded it successfully this year. Just yesterday, we played call options on Amgen inside the war room. Amgen was up three bucks. We already sold our call trade for a winner - while the market was going down. The individual names to watch: Novo Nordisk, Merck, Pfizer, Lilly. When the Mag 7 continues to sell off, this is where the rotation money lands. The timing couldn't be better. You've got a sector hitting all-time highs during market selloffs. You've got M&A catalysts creating a floor under these names. And you've got patent cliffs forcing big pharma to spend billions on deals. Money is moving. The question is: are you moving with it? While everyone else is staring at Greenland headlines and watching the Dow crater, smart money is rotating into the sectors that don't care about trade wars. Healthcare and biotech is one of those sectors. XBI just gave you the signal. The only question is whether you're paying attention. | 
Post a Comment
Post a Comment